1 The molecular basis of haemophilia A and B

https://doi.org/10.1016/S0950-3536(96)80059-XGet rights and content

Summary

Most families with haemophilia A or B carry gene defects of independent origin.

Haemophilia B is mostly due to small changes in the factor IX gene affecting either its transcription, mRNA maturation, mRNA translation or the fine structure of factor IX. Only 2–3% of patients show gross deletions or rearrangements. The great variety of missense mutations reported to cause haemophilia B indicates that this multidomain protein is highly constrained.

Less is known about the factor VIII gene as fully efficient mutation detection procedures only became available in 1991. This, however, led to the discovery that almost half the severe cases of haemophilia A or a fifth of all cases are due to frequently occurring inversions caused by homologous intra-chromosome (-chromatid) recombination between repeated sequences 9.5 kb long. Of the three repeats one is in intron 22 of the factor VIII gene and two are 400–500 kb more telomeric. They are 99.8% similar to each other. The spectrum of the other haemophilia A mutations is similar to that of haemophilia B.

Since 1983 mounting evidence has shown that in both haemophilias the nature of the mutation is important in predisposing to the inhibitor complication.

With regard to genetic counselling the best way to provide this service is through the construction of national confidential databases of mutations and pedigrees, as indicated by work in the UK on haemophilia B now being extended to haemophilia A.

References (64)

  • RowleyG et al.

    Ultrarapid mutation detection by multiplex, solid phase chemical cleavage

    Genomics

    (1995)
  • SheffieldVC et al.

    The sensitivity of single-strand conformation polymorphism analysis for the detection of single base substitutions

    Genomics

    (1993)
  • VidaudM et al.

    A de novo intragenic deletion of the potential EGF domain of the factor IX gene in a family with severe hemophilia B

    Blood

    (1986)
  • AgarwalaKL et al.

    Activation peptide of human factor IX has oligosaccharides O-glycosidically linked to threonine residues at 159 and 169

    Biochemistry

    (1994)
  • AlyAM et al.

    Hemophilia A due to mutations that create new N-glycosylation sites

  • ChenSH et al.

    An insertion within the factor IX gene: hemophilia B El Salvador

    American Journal of Human Genetics

    (1988)
  • CheungW-F et al.

    The binding of human factor IX to endothelial cells is mediated by residues 3–11

    Journal of Biological Chemistry

    (1992)
  • ChooKH et al.

    Molecular cloning of the gene for human antihaemophilic factor IX

    Nature

    (1982)
  • CrossleyM et al.

    Recovery from hemophilia B Leyden: an androgen-responsive element in the factor IX promoter

    Science

    (1992)
  • DombroskiBA et al.

    Isolation of an active human transposable element

    Science

    (1991)
  • FayPJ et al.

    Activated protein C—catalysed inactivation of human factor VIII and factor VIIIa: identification of cleavage sites and correlation of proteolysis with cofactor activity

    Journal of Biological Chemistry

    (1991)
  • FigueiredoMS et al.

    cis-acting elements and transcription factors involved in the promoter activity of the human factor VIII gene

    Journal of Biological Chemistry

    (1995)
  • FosterDC et al.

    The nucleotide sequence of the gene for human protein C

  • FreijeD et al.

    A 1.6 Mb contig of yeast artificial chromosomes around the human factor VIII gene reveals three regions homologous to probes for the DXS115 locus and two from the DXYS64 locus

    American Journal of Human Genetics

    (1992)
  • GiannelliF et al.

    Cause of the ‘inhibitor’ phenotype in the haemophilias

    Nature

    (1986)
  • GiannelliF et al.

    Gene deletions in patients with haemophilia B and anti-factor IX antibodies

    Nature

    (1983)
  • GiannelliF et al.

    Haemophilia B: database of point mutations and short additions and deletions

    Nucleic Acids Research

    (1990)
  • GiannelliF et al.

    Haemophilia B: database of point mutations and short additions and deletions, fifth edition, 1994

    Nucleic Acids Research

    (1994)
  • GitschierJ

    Maternal duplication associated with gene deletion in sporadic haemophilia

    American Journal of Human Genetics

    (1988)
  • GitschierJ et al.

    Characterization of the human factor VIII gene

    Nature

    (1984)
  • GreenPM et al.

    Haemophilia B mutations in a complete Swedish population sample. A test of new strategy for the genetic counselling of diseases with high mutational heterogeneity

    British Journal of Haematology

    (1991)
  • GreenPM et al.

    The haemophilias

  • Cited by (40)

    • Update on clinical gene therapy for hemophilia

      2019, Blood
      Citation Excerpt :

      Hemophilia is an X-linked monogenic coagulation disorder resulting from a deficiency in coagulation factors in the intrinsic coagulation cascade.1,2

    • Immune deviation by mucosal antigen administration suppresses gene-transfer-induced inhibitor formation to factor IX

      2006, Blood
      Citation Excerpt :

      In protein or gene replacement therapy for the X-linked bleeding disorders hemophilia A and B (deficiency in coagulation factor VIII or IX, respectively), the risk of production of antibodies that are inhibitory to clotting factor activity is a major concern. In conventional therapy, based on intravenous infusion of plasma-derived or recombinant protein, the incidence of inhibitors is 3% to 4% in hemophilia B and 20% to 30% in hemophilia A.1 Treatment of inhibitor patients is complicated and requires expensive bypass reagents such as protein complex concentrates and activated factor VII. Several protocols have been developed to eliminate inhibitors by frequent intravenous infusion of high doses of the clotting factor protein, often in combination with immunoglobulin infusion and immunosuppressive drug therapy.2

    • Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX gene therapy

      2006, Molecular Therapy
      Citation Excerpt :

      In the present studies, we found that hF.IX, as a non-self antigen to mice, when delivered by a viral vector, induced a CTL response. These findings have important implications for human hemophilia B gene therapy in that for some patients, normal F.IX is a new antigen [12,23] and can possibly induce a CTL response. One major impact is the identification of particular class I and class II MHC that are required to bind specific regions of AAV2, AAV8, or hF.IX antigen.

    View all citing articles on Scopus
    View full text